Hirulog-l {D-Phe-Pro-Arg-Pro- [Gly]4-desulphohirudin-(53-64) (HVl)} was designed to bind by its first four and last 12 residues to the a-thrombin catalytic site and anion-binding exosite for fibrin(ogen) recognition respectively, with a [Gly]4 bridge and an Arg-Pro bond at the scissional position. Human a-, y-and C-thrombins, as well as bovine trypsin, readily hydrolyse Spectrozyme-TH (D-hexahydrotyrosyl-Ala-Arg p-nitroanilide) at pH 7.4 and approx. 23 'C. Both a-and C-thrombins, which have high fibrinogen-clotting activities (> 3000 kunits/g), were inhibited with this substrate by hirulog-1 [K1 = 2.56 + 0.35 nm (n = 3) and 1.84 + 0.15 nm (n = 3) respectively] and slowly cleaved the inhibitor [k = 0.326 + 0.082 min-' (n = 12) and 0.362 + 0.056 min-1 (n = 18) respectively], whereas y-thrombin, which has essentially no clotting activity (approx. 4 kunits/g), and trypsin were not inhibited with > 1000-fold molar excess of hirulog-1.
INTRODUCTION
Procoagulant a-thrombih (EC 3.4.21.5 ) is the activation product of prothrombin in blood and has central bioregulatory functions in thrombosis/haemostasis, various disease states and wound healing (Fenton, 1981 (Fenton, , 1986 (Fenton, , 1988 Fenton et al., 1991) .
Other forms, such as ,l-thrombin and y-thrombin, which arise by autoproteolytic or tryptic fragmentation, are thermodynamically less stable than a-thrombin, and unlike it they essentially lack fibrinogen-clotting activity, but retain certain proteolytic capabilities (Bing et al., 1977; Fenton et al., 1977a Fenton et al., ,b, 1979 Chang et al., 1979 ; Lewis et al., 1987) . These forms are of questionable physiological importance, since physiological mechanisms for their generation have yet to be identified. In contrast, neutrophil elastase and cathepsin G cleave the B-chain of a-thrombin at Ala-I 50-Asn-1 51 and Tyr-148-Thr-149 bonds to generate e-and C-thrombins respectively, and these forms could arise in aging thrombi on neutrophil activation (Brower et al., 1987; Brezniak et al., 1990) . Like a-thrombin,~-thrombin retains high fibrinogen-clotting activity (Brezniak et al., 1990) and has similar inhibition constants (K1) with recombinant hirudin variants (Witting et al., 1991) , but is more readily denatured, like y-thrombin (Brezniak et al., 1990) .
Independently of its catalytic site and adjacent region (the traditional active site of serine proteinases), a-thrombin has an anion-binding exosite for fibrin(ogen) recognition and is blocked by hirudin . In contrast with hirudin, which blocks both clotting and tripeptide p-nitroanilide substrate activities, peptides corresponding to the highly negatively charged C-terminal approx. 20 % of hirudin inhibit the former but not the latter activities (Krstenansky & Mao, 1987; Mao et al., 1988; Fenton et al., 1989; Maraganore et al., 1989) . From these findings and the marked difference between hirudin binding with a-versus y-thrombin , the C-terminal tail of hirudin was concluded to bind at the exosite for fibrin(ogen) recognition, and the largely hydrophobic head to interact with apolar regions next to the catalytic site (Fenton, 1986 (Fenton, , 1988 (Fenton, , 1989 Fenton & Bing, 1986) . Indeed, recently detemined crystallographic structures of human a-thrombin complexes with recombinant hirudin variants have confirmed such bivalent or bridge binding (Grutter et al., 1990; Rydel et al., 1990) . In addition, athrombin also appears to have another anion-binding exosite for heparin binding (Church et al., 1989) and perhaps other substances .
Before there was any knowledge of the crystallographic structures of human a-thrombin (Bode et al., 1989) and its complexes with recombinant hirudins (Grutter et al., 1990; Rydel et al., 1990) , hirulog-l {D-Phe-Pro-Arg-Pro-[Gly]4-desulphohirudin-(53-64) (HVI)} was designed so that the first four and last 12 residues would interact with regions adjacent to the catalytic site and the anion-binding exosite for fibrin(ogen) recognition of a-thrombin respectively . The D-Phe-Pro-Arg ligand was chosen because of its high affinity for the catalytic site and adjacent regions (Bajusz et al., 1978; Kettner & Shaw, 1978; Witting et al., 1988) , and a proline residue was subsequently added to form an imide bond thought to prevent cleavage (Bagdy et al., 1976; Fenton & Bing, 1986) . The length of the flexible [Gly]4 spacer was initially based on affinity-labelling experiments with hirudin-(53-64) that indicated a distance of approx. 1.8 nm (18 A) from the catalytic site to the exosite and was subsequently determined by varying the number of glycine residues from two to eight ing to Tyr-63 in hirudin) was unnecessary and desulphohirudin-(53-64) was used as the second ligand. Subsequent to our initial report , we found that hirulog-l is a slow-turnover inhibitor of ac-and C-thrombins . Similar hirudin derivatives have been reported by others (Di Maio et al., 1990) , and non-cleavable analogues have been reported by both groups of investigators (Di Maio et al., 1991; Kline et al., 1991) . The present paper reports detailed kinetics for cleavage of the Arg-3-Pro-4 bond in hirulog-1 by human a-and -thrombins. Neither y-thrombin nor trypsin was inhibited, demonstrating that hirulog-1 is specific for thrombin forms with high clotting activities.
EXPERIMENTAL Chemicals and reagents
Hirulog-1 was prepared and characterized as previously described Human a-thrombin was prepared from fraction III paste as previously described (Fenton et al., 1977a,b) . It was converted into y-or (-thrombin by controlled passage through trypsin-or chymotrypsin-immobilized Sepharose 4B respectively (Bing et al., 1977; Fenton et al., 1977b; Brezniak et al., 1990 ). An absorption coefficient of 1.75 litre g--cm-' was used for all thrombin forms in 1.0 M-acetic acid, and an Mr of 36500 was assumed for these forms. Preparations were evaluated (Table 1) and stored at -70°C in 0.75 M-NaCl until used (Fenton et al., 1977a,b) .
Spectrozyme-TH amidolytic activities
A Varian 210 dual-beam u.v.-visible recording spectrophotometer was used where reactions were carried out in 1.0 cmpathlength polystyrene semi-micro cuvettes (Sarstedt, Princeton, NJ, U.S.A.) at approx. 23 'C. Enzyme concentrations were based on active-site titrations with p-nitrophenyl p'-guanidinobenzoate (Table 1) , whereas Spectrozyme-TH concentrations were determined from the 342 nm isosbestic absorption coefficient of 9920 M-1 cm-' for it and p-nitroanilide at a 1'0 nm bandwidth (Witting et al., 1991) . Reactants were dissolved and subsequently diluted in 150 mM-NaCl/10 mM-Hepes/10 mM-Tris buffer, pH 7.4, containing 2.5 g of poly(ethylene glycol) 6000/1. Spectrozyme Table 2 ).
To determine Ki values, the above procedure was used except that enzyme (Table 3) was incubated with various amounts of hirulog-I for various times at approx. 23°C before assay. Because of the high-affinity binding of hirulog-1 to thrombin, an allowance becomes necessary to correct for the reduction in inhibitor concentration that occurs on formation of the enzymeinhibitor (El) complex (Morrison, 1969 (Morrison, , 1982 Henderson, 1972; . Therefore the variation of the steadystate velocity (v,) with total inhibitor (I) is expressed in eqn. (2) (Morrison, 1969; Henderson, 1972) :
_K + -t2 (Ki + It-_Et) (2) Here v0 is the velocity observed in the absence of the inhibitor, Et is the total enzyme concentration, and Ki is the apparent inhibition constant, which is related to K, by eqn. (3):
During determination of the K, of hirulog-1, the concentrations of Spectrozyme-TH, a-thrombin and (-thrombin were kept constant at 18,M, 5.51 nm and 5.23 nM respectively, and the concentration of hirulog-1 was varied from 0 to 95 nm. The K1 of hirulog-1 for both thrombin forms was determined by obtaining steady-state velocities at zero incubation time with six concentrations of hirulog-1. These velocities were fitted by non-linear regression to eqn. (2) with Minsq. K, was subsequently converted into K, by using eqn. (3). The K, values from three different runs were averaged. For the determination of the rate constant, k, for the destruction of hirulog-1, measurements were obtained every 5 min at all five concentrations until all the inhibitor was inactivated.
In the determination of k for hirulog-1 consumption from progress curves, the velocity (v.) of substrate hydrolysis was proportional to the enzyme-substrate complex (ES) concentration, whereas in the absence of inhibitor the velocity (v0) was proportional to the total enzyme (Et 
This allows the calculation of k for the destruction of the inhibitor according to eqn. (6) (Goldstein, 1944) :
Here io is i at time zero, EI is Eo/Ki, and t is the time of duration of the enzyme-inhibitor reaction. Least-squares analysis provided by the Minsq software program was used to obtain v1/v0
and k values.
Fibrinogen-clotting activities Clotting times were determined with a fibrometer equipped with a 0.40 ml probe and a constant-temperature block at 37 'C. Fibrinogen was reconstituted at 8.0 g/l in 150 mM-NaCI buffered with 10 mM-imidazole at pH 7.4, whereas the thrombins and/or hirulog-1 were diluted in 150 mM-NaCI/30 mM-CaC12/ 10 mM-imidazole buffer, pH 7.4, containing 8.8 g ofpoly(ethylene glycol) 6000/1 (Fenton & Fasco, 1974) . Concentrations of 8.29 nm and 8.64 nm for a-thrombin and C-thrombin respectively were incubated with seven concentrations of 0 nm-to 95 nM-hirulog-1 at approx. 23 'C for various times. To assay, 100 ,d of the incubated mixture was added to 200 zl of the preceding dilution buffer that had been prewarmed to 37 'C in a fibrometer cup. Clotting was then initiated by adding 100 ,ul offibrinogen solution with the fibrometer pipette, which activated the timer. Control samples (without hirulog-l) were also assayed twice every 5 min in between each hirulog-1 run, and this procedure was repeated three times for both a-thrombin and C-thrombin. Hirulog-1 samples were assayed immediately on mixing (t = 0) and then twice every 5 min until the control clotting time was obtained.
Although the clotting assay measures an end point, clotting times are an inverse velocity function and are linearly related to the reciprocal thrombin concentration in clotting units (CU) . From this relationship, the ratio of the inhibited thrombin activity (CU.) to the control activity (CU0) of thrombin alone is equal to the corresponding velocity ratio (v8/v0) and K1 was determined by eqns. (2) and (3), where 7.2 /uM was used for the Km for fibrinogen Aa cleavage by thrombin (Higgins et al., 1983) , assuming that this cleavage is rate-limiting . The inhibition (i) fraction is 1 -(CUS/CUO). Values for k were determined from eqns. (4), (5) and (6).
Thrombin cleavage of hirulog-1
Hirulog-1 at 232 /M was incubated overnight at approx. 23°C with 1.8 ,sM-a-or C-thrombin in 100 mM-NaCl/50 mM-Na3BO3, pH 8.4. These incubation mixtures were then chromatographed by reverse-phase h.p.l.c. on an Aquapore C. RP-300 column (0.46 mm x 100 mm) (Rainin, Emeryville, CA, U.S.A.) equilibrated with 0.1 % (v/v) trifluoroacetic acid in water and developed with a linear gradient of 0-35 % (v/v) acetonitrile in water over 45 min at 1.0 ml/min. The effluent was monitored at 214 nm, and peaks were collected manually. Products from athrombin incubation were identified by automated Edman degradation as described elsewhere .
RESULTS AND DISCUSSION
The thrombin preparations used met specifications for high purity and enzyme activities (Table 1) . These preparations contained more than 90 % of their respective forms and titrated with p-nitrophenyl p'-guanidinobenzoate to more than 80% active enzyme. Both a-thrombin and C-thrombin possessed specific clotting activities of more than 3000 kCU/g, whereas ythrombin had 800-fold less clotting activity. Since trypsin cleaves three residues beyond the Aa-cleavage site for a-thrombin in fibrinogen (Lewis et al., 1987) and lacks true clotting activity, this activity was not examined, but the trypsin preparation was 94 % active on p-nitrophenyl p-guanidinobenzoate titration.
Like a-, y-and C-thrombins, trypsin cleaves Spectrozyme-TH and exhibits a specificity constant (kcat./Km) more similar to ythrombin than to a-or C-thrombin (Table 2) . Although within + 2 S.E.M., C-thrombin has the lowest Km of the four preparations, indicating a slightly greater affinity, which is consistent with its higher p-nitrophenyl p'-guanidinobenzoate titration value (Table   1) . Furthermore, C-thrombin binds somewhat more tightly to Amberlite CG-50 resin (cross-linked polymethylacrylic acid) (Brezniak et al., 1990 ) and slightly more strongly to recombinant hirudin HVY and HV2K47 variants than does a-thrombin (Witting et al., 1991) . Whereas both a-thrombin and C-thrombin were inhibited by hirulog-1 in both Spectrozyme-TH amidolytic and clotting assays, neither y-thrombin nor trypsin was inhibited in the amidolytic assay with more than 1000-fold molar excess of hirulog-1 (Table 3) . This finding thus demonstrates that clotting activity and inhibition by hirulog-1 are correlated. Such a Table 1 . Evaluation of human thrombin and bovine trypsin preparations Preparations were analysed as described elsewhere (Fenton et al., 1977a,b; Brezniak et al., 1900 Vol. 283 (#M-1. s-1)
1.87 +0.37 (n = 8) 2.39 + 0.92 (n = 3) 1.10+0.37 (n = 3) 3.47 + 0.73 (n = 4) 27.7 + 3.3 (n = 8) 24.0 + 4.9 (n = 3) 17.0 + 3.1 (n = 3) 24.1 + 4.2 (n = 4) 7.85 /M-hirulog-1 correlation requires that both the catalytic site and adjacent regions and the fibrin(ogen) recognition exosite be involved, which is after all the design of hirulog-1 (see the Introduction). While carrying out detailed kinetic experiments with hirulog-1 by tight-binding analysis, we found that, unlike with hirudin (Witting et al., 1991) , the potency of hirulog-I depended on the length of incubation time with a-thrombin. This time-dependency was observed for incubations with either a-or C-thrombin assayed by amidolytic and clotting assays (Table 3 and Fig. 1 ). These incubations were carried out at approx. 23°C because both thrombins exhibit similar stabilities at this temperature, in contrast with 37°C, where C-thrombin is less stable than athrombin (Brezniak et al., 1990) . The observed loss of inhibitory activities thus suggested that hirulog-1 was being consumed by degradation (e.g. enzyme cleavage) or by loss (e.g. vessel wall adsorption, phase partitioning). The most likely explanation of the cleavage of the Arg-3-Pro-4 bond was verified by incubating hirulog-1 with either a-or C-thrombin overnight at pH 8.4 and approx. 23 'C. Both incubation mixtures gave identical products on h.p.l.c. being eluted with 9.8 or 9.8 % and with 26.5 or 26.7 % acetonitrile for a-or C-thrombin incubations respectively. For the a-thrombin products, the first was identified as the Nterminal fragment by three Edman degradation cycles and the second as the C-terminal fragment by 17 cycles, thus establishing the single cleavage at the Arg-3-Pro-4 bond in hirulog-1.
Because hirulog-1 is hydrolysed, our previously reported value of 2.3 nm ) must be considered as a Ki' value, and the true Ki must be defined at time zero before any degradation. The turnover rate k thus describes the cleavage rate.
Because of the nanomolar value for Ki', these values were determined by the tight-binding method (Morrison, 1969 (Morrison, , 1982 Henderson, 1972) , as employed for thrombin-hirudin binding Stone et al., 1987; Braun et al., 1988; Witting et al., 1991) . Implicit in the derivation of the expressions in this method is the assumption of competitive inhibitions. That hirulog-1 behaved as a competitive inhibitor of Spectrozyme-TH hydrolysis by a-thrombin is shown by the common intercept on the ordinate of the plot of 1/v1 versus 1/S (Mahler & Cordes, 1966) (Fig. 2) . Values for k were calculated on the basis of a consumptive inhibitor model (Goldstein, 1944) . Although the incubations of hirulog-1 and the Spectrozyme-TH amidolytic assays were carried out at approx. 23°C, the fibrinogen-clotting assays were at 37 'C. In further contrast, the amidolytic assay is kinetic, whereas the clotting assay measures the time for an end point. Nevertheless, clotting 15 values (i.e. concentrations giving 50% inhibition) approximate K', which can be converted into a Ki estimate on the assumption that the fibrinogen Aa cleavage is rate-limiting in the clotting process . Such approximations are applicable for moderate-affinity inhibitors but not for those with very high affinities (Webb, 1963) (Table 3) Starting at the zero-time incubation, duplicate determinations were made every 5 min until hirulog-I became inactive. Duplicate control samples without hirulog-1 were assayed before the zero-time incubation, between each determination and after the final determination.
the k/K1 ratios for these data range from 2.1 to 3.6 /Mm-1 s s-and are an order of magnitude lower than those from the kcat /Km ratios for Spectrozyme-TH (Table 2 ) and other tripeptide pnitroanilide substrates (Witting et al., 1987) , as well as fibrinogen Aa cleavage by a-thrombin (Higgins et al., 1983 high affinity of hirulog-1 for a-thrombin, with the consequence that hirulog-1 is a highly effective inhibitor of fibrinogen clotting.
On the other hand, the nanomolar Ki value of a-thrombin for hirulog-1 is similar to that for thrombomodulin (Owen & Esmon, 1981; Hofsteenge et al., 1986; Jakubowski et al., 1986) and to the Kd values for high-affinity binding sites on platelets (Martin et al., 1976) , fibroblasts (Glenn et al., 1980; Perdue et al., 1981) as well as endothelial cells (Awbrey et al., 1979) . This would suggest that high-affinity binding proteins or sites on various cell types should compete for a-thrombin in vivo. However, a-thrombin is actively incorporated into the forming fibrin clot (or thrombus), where it remains partitioned from the blood (Wilner et al., 1981) . Such thrombus-entrapped thrombin is protected from bloodborne inhibitors, such as antithrombin III, which cannot readily permeate the fibrin matrix (Weitz et al., 1990) and is believed to serve as a source for thrombin in post-clotting and woundhealing events (Fenton, 1988; Fenton et al., 1991) .
Hirudin is approx. 3-fold larger than hirulog-1, and its complex with a-thrombin is essentially irreversible even though it is noncovalent because of the upper to mid femtomolar K1 values of the complex Braun et al., 1988; Witting et al., 1991) . The hirulog-1 complex in contrast has four to five orders of magnitude less affinity and presumably forms an enzyme-substrate (or inhibitor) complex that was found to turn over slowly (Table 3) . Furthermore, the first cleavage product (residues 4-20) of hirulog-1 contains the desulphonated hirudin tail fragment 'hirugen', which has a micromolar K1 value for athrombin (Maraganore et al., 1989) . Thus hirulog-l is hydrolysed to a mild thrombin inhibitor, which should not interfere with thrombin generation amplification (e.g. Factor V and Factor VIII activation) and should be less apt to cause any bleeding tendencies . Moreover, thrombin regenerated from the hirulog-1 complex could be cleared by inhibitors in blood (e.g. antithrombin III) or have beneficial functions in healing processes (Fenton, 1988) .
Hirulog-1 was designed before there was any knowledge of the crystallographic structure of a-thrombin and complexes with hirudins and was designed so that it binds to and bridges between the thrombin catalytic site and exosite for fibrinogen recognition (see the Introduction). Although the Pro-2-Arg-3-Pro-4 sequence in hirulog-1 resembles that of Pro-46-Lys-47-Pro-48 in hirudin HVI, Lys-47 is not a prerequisite for hirudin complexformation, since it is replaced by asparagine in hirudin HV2 (Harvey et al., 1986; Degryse et al., 1989) and by other residues in various recombinant hirudins without substantial loss in inhibitory activities (Braun et al., 1988; Dodt et al., 1988; Degryse et al., 1989) . Furthermore, when Pro-48 is replaced by alanine, a-thrombin does not cleave this hirudin variant (Dodt et al., 1990) , as would be predicted by the present data if Lys-47 were accessible to the catalytic apparatus of the enzyme. In the crystallographic structure of the a-thrombin-hirudin complex, Lys-47 projects away from the specificity pocket to interact with Trp-60D (chlymotrypsin numbering) in the thrombin B-chain (Rydel et al., 1990) . Thus, in agreement with the long-recognized fact that the thrombin-hirudin complex is non-covalent (Markwardt, 1970; Fenton et al., 1979) , the hirudin Lys-47-Pro-48 bond is inaccessible to the thrombin catalytic apparatus and is consequently non-cleavable. Nevertheless, the present finding that thrombin can slowly cleave an imide Arg-Pro bond suggests that hirudin may have evolutionarily evolved from a protein with a Lys-Pro (or Arg-Pro) linkage, whose mechanism of inhibition was that of slow cleavage of an imide bond to one where such a linkage is inaccessible to proteolysis by thrombin. In these regards, examples of slowly cleaved imide bonds in proteins may be found where such proteins serve as slow turnover inhibitors or those with delayed activation functions.
In summary, hirulog-1 is a bivalent 20-residue peptide designed to bridge-bind at regions adjacent to the catalytic site and at the anion-binding exosite for fibrin(ogen) recognition. It is a specific inhibitor of thrombin forms with high clotting activities (aand~-thrombins) and is slowly cleaved at its Arg-3-Pro-4 bond.
